help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GILBERT, B. E.
Right arrow Articles by ESCHENBACHER, W. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GILBERT, B. E.
Right arrow Articles by ESCHENBACHER, W. L.

Am. J. Respir. Crit. Care Med., Volume 156, Number 6, December 1997, 1789-1793

Tolerance of Volunteers to Cyclosporine A-dilauroylphosphatidylcholine Liposome Aerosol

BRIAN E. GILBERT, CAROLINE KNIGHT, FRANCISCO G. ALVAREZ, J. CLIFFORD WALDREP, JOSEPH R. RODARTE, VERNON KNIGHT, and WILLIAM L. ESCHENBACHER

Departments of Microbiology and Immunology, Medicine, and Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, Texas

Cyclosporine A (CsA) in liposomes of dilauroylphosphatidylcholine (DLPC), containing 118 µg of CsA/L of aerosol with a particle size of 1.6 to 1.7 µm diameter, was inhaled by 10 nonsmoking, normal volunteers each for 45 min. Aerosol was administered through an Aerotech II nebulizer (CIS-US, Inc., Bedford, MA) mouthpiece. Eight of the 10 volunteers had tracheal irritation and intermittent coughing following exposure. FEV1 and FVC values were mildly reduced, but returned to normal in 1 h. Blood chemical and hematologic values were unchanged at any time point after as opposed to before inhalation. Nine of the 10 volunteers later inhaled DLPC only, administered through the nebulizer mouthpiece. There was no change in FEV1 or FVC values, and there was no coughing or tracheal irritation. Subsequently, five of the volunteers who had previously had respiratory reactions inhaled CsA-DLPC liposome aerosol for 45-min, but through a mouth-only face mask. There was no tracheal irritation, coughing, or changes in spirometric measures. Blood concentrations of CsA at 15 min after the 45-min inhalation with a face mask averaged 83 ± 42 ng/ml (mean ± SD). At 24 h after treatment, CsA was undetectable in blood of the initial 10 volunteers. These studies indicate that CsA-DLPC liposome aerosol can be safely explored as a treatment for patients with moderately severe asthma.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
C. F. Verschraegen, B. E. Gilbert, E. Loyer, A. Huaringa, G. Walsh, R. A. Newman, and V. Knight
Clinical Evaluation of the Delivery and Safety of Aerosolized Liposomal 9-Nitro-20(S)-Camptothecin in Patients with Advanced Pulmonary Malignancies
Clin. Cancer Res., April 1, 2004; 10(7): 2319 - 2326.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
L. N. KHAN, O. M. KON, A. J. MACFARLANE, Q. MENG, S. YING, N. C. BARNES, and A. BARRY KAY
Attenuation of the Allergen-induced Late Asthmatic Reaction by Cyclosporin A Is Associated with Inhibition of Bronchial Eosinophils, Interleukin-5, Granulocyte Macrophage Colony-Stimulating Factor, and Eotaxin
Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): 1377 - 1382.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
G. V. Letsou, H. J. Safi, M. J. Reardon, M. Ergenoglu, Z. Li, C. N. Klonaris, J. C. Baldwin, B. E. Gilbert, and J. C. Waldrep
Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression
Ann. Thorac. Surg., December 1, 1999; 68(6): 2044 - 2048.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1997 American Thoracic Society